How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

RXRX has reported updated data from its ELUCIDATE and TUPELO trials, but the stock has failed to mount a sustained rally. The ELUCIDATE update provides just an additional 10 patients of data treated ...

No Tail To Tell, the new Korean rom-com on Netflix, involves a lot of mysticism interacting with the real world in the current day. Given the history of romantic K-dramas, though, it doesn’t seem like ...

Java Development Kit (JDK) 26, a planned update to standard Java due March 17, 2026, has reached the initial release candidate (RC) stage. The RC is open for critical bug fixes, with the feature set ...

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...